Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 56 , ISSUE 2 ( April-June, 2022 ) > List of Articles

Original Article

Management of Skin Malignancies: Lessons Learnt at a Tertiary Care Center in Northern India

Siddhant Khare, Abhinav Singh, Palak Singhai, Rajender Kumar, Debajyoti Chatterjee, Santosh Irrinki

Keywords : BCC, DMFSP, Melanoma, Merkel cell carcinoma, SCC, Skin cancer

Citation Information : Khare S, Singh A, Singhai P, Kumar R, Chatterjee D, Irrinki S. Management of Skin Malignancies: Lessons Learnt at a Tertiary Care Center in Northern India. J Postgrad Med Edu Res 2022; 56 (2):63-69.

DOI: 10.5005/jp-journals-10028-1567

License: CC BY-NC 4.0

Published Online: 07-06-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Introduction: The prognosis of skin cancers in India is worse when compared to the Western countries. It may be because of overall rarity and low experience at individual centers, presentation with advanced disease, inadequate first treatment and a higher incidence of poor prognostic disease subtypes. Aims and objectives: To analyze the clinicopathological characteristics, recurrence patterns and the completeness of first treatment in the patients with skin cancers. Materials and methods: It was a retrospective analysis of all patients operated for skin cancers. Mean and SD was computed for normal data; for skewed data, median and IQR were used. Kaplan-Meier analysis was used to assess the survival. Results: There were 18 cases of skin malignancies of which 8 (44.4%) patients had MM 5 (27.8%) had SCC 2 (11.1%) each had BCC and DMFSP and 1 (5.6%) had MCC. Pain was the most common presenting symptom (55.6%). The median follow-up was 12.25 months (Range 2–21.5 months). Ten (55.6%) patients had received a primary treatment elsewhere, not in accordance with the standard treatment guidelines. The median delay between the primary treatment and definitive surgery was 8 months (Range 2.5–48 months) which led to an increase in surgical morbidity in at least 4 (40%) of these patients. Median disease-free survival in the study was 12 months. Conclusion: Skin cancers have poor outcomes in Indian patients when compared to the Western countries. Awareness programs for early diagnosis, a high index of suspicion and early referral to a center experienced in handling these malignancies may help in improving outcomes.

  1. Apalla Z, Lallas A, Sotiriou E, et al. Epidemiological trends in skin cancer. Dermatology Practical & Conceptual 2017;7(2):1–6. DOI: 10.5826/dpc.0702a01
  2. GLOBOCAN 2018 Australia [Internet]. 2020 [cited 17 May 2020]. Available from:
  3. Perera E, Sinclair R. An estimation of the prevalence of nonmelanoma skin cancer in the U.S. F1000Res 2013;2:107. DOI: 10.12688/f1000research.2-107.v1
  4. GLOBOCAN 2018 USA [Internet]. 2020 [cited 17 May 2020]. Available from:
  5. GLOBOCAN 2018 India [Internet]. 2020 [cited 17 May 2020]. Available from:
  6. Schadendorf D, Lebbé C, Hausen AZ, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. European Journal of Cancer 2017;71:53–69. DOI: 10.1016/j.ejca.2016.10.022
  7. Ruiz R, Morante Z, Mantilla R, et al. Primary cutaneous T-cell lymphoma: experience from the Peruvian national cancer institute. An Bras Dermatol 2017;92(5):649–654. DOI: 10.1590/abd1806-4841.20176825
  8. Cesarman E, Damania B, Krown S, et al. Kaposi sarcoma. Nature Reviews Disease Primers 2019;5(1). DOI:
  9. Cao J, Wang J, He C, et al. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res 2019;9(11):2303-2313
  10. Deo SV, Hazarika S, Shukla NK, et al. Surgical management of skin cancers: experience from a regional cancer centre in North India. Indian J Cancer 2005;42(3):145–150. DOI: 10.4103/0019-509x.17059
  11. Nair MK, Varghese C, Mahadevan S, et al. Cutaneous malignant melanoma- clinical epidemiology and survival. J Indian Med Assoc 1998;96:19–20
  12. Vijaykumar DK, Kannan RR, Chaturvedi HK. Plantar acral melanoma-an experience from a regional cancer centre, India. Indian J Cancer 1996;33(3):122–129.
  13. [Internet]. 2020 [cited 15 May 2020]. Available from:
  14. [Internet]. 2020 [cited 15 May 2020]. Available from:
  15. [Internet]. 2020 [cited 15 May 2020]. Available from:
  16. [Internet]. 2020 [cited 15 May 2020]. Available from:
  17. [Internet]. 2020 [cited 15 May 2020]. Available from:
  18. National Cancer Registration and Analysis Service. Routes to diagnosis of cancer by stage 2012–2013 workbook. London: NCRAS; 2016.
  19. Spillane AJ, Pasquali S, Haydu LE, et al. Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden. Ann Surg Oncol 2014;21(1):292–299. DOI: 10.1245/s10434-013-3253-6
  20. Clayman G, Lee J, Holsinger F, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005;23(4):759–765. DOI: 10.1200/JCO.2005.02.155
  21. Wiesmueller F, Agaimy A, Perrakis A, et al. Dermatofibrosarcoma protuberans: surgical management of a challenging mesenchymal tumor. World J Surg Oncol 2019;17(1). DOI: 10.1186/s12957-019-1627-3
  22. Meyer-Pannwitt U, Kummerfeldt K, Boubaris P, et al. Merkel cell carcinoma. Langenbecks Archiv für Chirurgie 1997;382(6):349.
  23. Sharma K, Mohanti BK, Rath GK. Malignant melanoma: a retrospective series from a regional cancer center in india. J Cancer Res Ther 2009;5(3):173–180. DOI: 10.4103/0973-1482.57122
  24. Veness MJ, Morgan GJ, Palme CE, et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005;115(5): 870–875. DOI: 10.1097/01.MLG.0000158349.64337.ED
  25. Enninga E, Moser J, Weaver A, et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med 2017;6(10):2203–2212. DOI: 10.1002/cam4.1152
  26. Endo Y, Tanioka M, Miyachi Y. Prognostic factors in cutaneous squamous cell carcinoma: is patient delay in hospital visit a predictor of survival? ISRN Dermatol 2011;2011:285289. DOI: 10.5402/2011/285289
  27. Koolen P, Matos T, Ibrahim A, et al. Recurrence rates over 20 years in the treatment of malignant melanoma. Plast Reconstr Surg Glob Open 2017;5(7):e1378. DOI: 10.1097/GOX.0000000000001378
  28. Smith J, Virk S, Palme C, et al. Age is not a predictor of prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2016;88(4):E273–E277. DOI: 10.1111/ans.13757
  29. Cavanaugh-Hussey M, Mu E, Kang S, et al. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003–2011). Ann Surg Oncol 2015;22(7):2120–2126. DOI: 10.1245/s10434-015-4538-8
  30. Melanoma Skin Cancer Statistics [Internet]. 2020 [cited 25 May 2020]. Available from:
  31. Kirkwood J, Jukic D, Averbook B, et al. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol 2009;36(5):419–431. DOI: 10.1053/j.seminoncol.2009.07.001
  32. Mullen J, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006;13(7):902–909. DOI: 10.1245/ASO.2006.07.022
  33. Garbe C, Büttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;75(10):2492–2498. DOI: 10.1002/1097-0142(19950515)75:10<2492::aid-cncr2820751015>;2-w
  34. Bradford P, Goldstein A, McMaster M, et al. Acral lentiginous melanoma. Arch Dermatol 2009;145(4). DOI: 10.1007/3-540-29668-9_48
  35. O'Shea S, Rogers Z, Warburton F, et al. Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study. BMC Cancer 2017;17(1):5. DOI: 10.1186/s12885-016-2978-6
  36. Iannacone MR, Green AC. Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. Melanoma Manag 2014;1(1):75–84. DOI: 10.2217/mmt.14.6
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.